Profile for Canada Patent: 2822854

US Patent Family Members and Approved Drugs for Canada Patent: 2822854

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
9,023,897	Apr 5, 2033	Teva	UZEDY	risperidone

Key insights for pharmaceutical patentability - Canada patent CA2822854

Last updated: April 25, 2026

What does Canadian patent CA2822854 cover, and how does it shape the patent landscape?

What is the patent’s core identity (title, status, parties, and key bibliographic facts)?

CA2822854 is a Canadian patent publication/registration (assignee listed in the publication record) tied to a specific therapeutic invention set out in its claims. The patent’s scope is defined primarily by its independent claims and any dependent claim structure (formulations, dosages, methods of use, and/or compound definitions), and by how closely those claims map to the granted or allowed subject matter in Canada.

The complete and reliable claim-by-claim scope, including:

• independent claim wording,
• dependent claim limitations,
• claim numbering and claim status (granted vs. pending, if any),
• and legal status events (grants, term adjustments, disclaimers, amendments),

is not available in the input provided here. Under these constraints, a full and accurate legal-scope assessment cannot be produced.

How do you determine the scope: what claim categories likely drive coverage?

For Canadian drug patents such as CA2822854, the actionable scope almost always falls into one or more of these claim categories:

1. Compound claims (chemical structure coverage)
   Coverage hinges on exact structural definitions, Markush breadth, stereochemistry, salt/hydrate definitions, and substituent constraints.

2. Composition claims (formulation coverage)
   Coverage hinges on excipients, drug substance form (salt/polymorph), concentration ranges, and manufacturing/physical property limitations.

3. Method-of-treatment claims (indication/dosing coverage)
   Coverage hinges on the patient population, disease stage, treatment regimen, dosing frequency, dose range, and clinical endpoints.

4. Use claims tied to a specific therapeutic regimen
   Coverage depends on the novelty of the regimen and whether it is bound tightly to a specific schedule or dosing parameters.

5. Process claims (manufacturing coverage)
   Coverage hinges on process steps and conditions (temperatures, solvents, catalysts, purification steps).

Without the actual claim text for CA2822854, any mapping to these categories would be speculative.

What does the “patent landscape” analysis require for CA2822854?

A credible landscape for CA2822854 needs, at minimum:

• Family mapping: priority filings, PCT/WO equivalents, and related jurisdictions (US/EU/UK/AU/CA).
• Claim alignment across jurisdictions: whether US/EPO claims were narrowed or broadened relative to Canada.
• Regulatory linkage (where applicable): whether the patent is listed under Canada’s Patented Medicines (NOC/c) framework for a specific DIN/NOC product and the listed use.
• Litigation and enforcement signals: NOC-related proceedings tied to that patent, if any.
• Expiry and exclusivity: patent term, any adjustments, and earliest expiration among family members (and Canada-specific events).

None of the above facts (family members, regulatory status, NOC listing, or litigation posture) are included in the provided input, so a complete landscape cannot be produced without introducing inaccuracies.

What can be stated from CA2822854 alone, without claim text or legal records?

Nothing beyond the identifier itself can be stated without risking incorrect legal scope.

CA2822854’s “scope and claims” and the “patent landscape” are intrinsically claim- and event-specific. A Bloomberg-style deliverable must rest on:

• the exact claim language,
• the legal status and amendments,
• and the enforcement and linkage context in Canada.

Those elements are not present in the provided material.

---

Key Takeaways

• A complete, accurate analysis of CA2822854’s claim scope and its impact on Canada’s patent landscape requires the patent’s actual claim text and Canada-specific legal/regulatory linkage data.
• No scope, infringement/avoidance angles, or comparative landscape positioning can be provided from the patent identifier alone without producing potentially incorrect results.

FAQs

1. Can you summarize CA2822854’s claim scope without the claim text?
   No. Claim scope in drug patents is defined by exact wording and dependent limitations.

2. Can you map CA2822854’s family and landscape without priority and legal status data?
   No. Landscape assessment requires family and jurisdiction-level claim and event alignment.

3. Does CA2822854 likely include compound, formulation, and method claims?
   Many drug patents do, but CA2822854’s actual categories cannot be confirmed here without the claims.

4. Can you identify whether CA2822854 is listed for a specific DIN under the NOC/c system?
   Not from the information provided.

5. What is the minimum dataset needed to deliver the requested analysis?
   The CA2822854 claim set and Canada legal/regulatory linkage records plus family mapping.

---

References

[1] (No sources provided in the input.)